Data on Retinal Diseases and Conditions Reported by Researchers at University of Missouri - Kansas City (Off-label use of bevacizumab in the treatment of retinal disease: ethical implications)

Source :: Immunotherapy Weekly. December 18, 2019, 686
Publication Year :: 2019
Abstract: 2019 DEC 18 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in Eye Diseases and Conditions - Retinal Diseases and Conditions. According [...]

Subjects :: University of Missouri-Kansas City -- Ethical aspects
Care and treatment
Ethical aspects
Bevacizumab -- Ethical aspects
Retinal diseases -- Care and treatment
Vascular endothelial growth factor
Medical research
Immunotherapy
Colorectal cancer -- Care and treatment
Endothelium
Eye diseases
Angiogenesis inhibitors
Antineoplastic agents
Endothelial growth factors
Editors

Tools